Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential.
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Mabs
Wingert, Susanne S; Reusch, Uwe U; Knackmuss, Stefan S; Kluge, Michael M; Damrat, Michael M; Pahl, Jens J; Schniegler-Mattox, Ute U; Mueller, Thomas T; Fucek, Ivica I; Ellwanger, Kristina K; Tesar, Michael M; Haneke, Torsten T; Koch, Joachim J; Treder, Martin M; Fischer, Wolfgang W; Rajkovic, Erich E
Biphasic Mathematical Model of Cell-Drug Interaction That Separates Target-Specific and Off-Target Inhibition and Suggests Potent Targeted Drug Combinations for Multi-Driver Colorectal Cancer Cells.
Cancers
Shen, Jinyan J; Li, Li L; Yang, Tao T; Cohen, Paul S PS; Sun, Gongqin G
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
Nature Communications
Sale, Matthew J MJ; Minihane, Emma E; Monks, Noel R NR; Gilley, Rebecca R; Richards, Frances M FM; Schifferli, Kevin P KP; Andersen, Courtney L CL; Davies, Emma J EJ; Vicente, Mario Aladren MA; Ozono, Eiko E; Markovets, Aleksandra A; Dry, Jonathan R JR; Drew, Lisa L; Flemington, Vikki V; Proia, Theresa T; Jodrell, Duncan I DI; Smith, Paul D PD; Cook, Simon J SJ
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
Nature Communications
Menden, Michael P MP; Wang, Dennis D; Mason, Mike J MJ; Szalai, Bence B; Bulusu, Krishna C KC; Guan, Yuanfang Y; Yu, Thomas T; Kang, Jaewoo J; Jeon, Minji M; Wolfinger, Russ R; Nguyen, Tin T; Zaslavskiy, Mikhail M; , ; Jang, In Sock IS; Ghazoui, Zara Z; Ahsen, Mehmet Eren ME; Vogel, Robert R; Neto, Elias Chaibub EC; Norman, Thea T; Tang, Eric K Y EKY; Garnett, Mathew J MJ; Veroli, Giovanni Y Di GYD; Fawell, Stephen S; Stolovitzky, Gustavo G; Guinney, Justin J; Dry, Jonathan R JR; Saez-Rodriguez, Julio J
Sale, Matthew J MJ; Balmanno, Kathryn K; Saxena, Jayeta J; Ozono, Eiko E; Wojdyla, Katarzyna K; McIntyre, Rebecca E RE; Gilley, Rebecca R; Woroniuk, Anna A; Howarth, Karen D KD; Hughes, Gareth G; Dry, Jonathan R JR; Arends, Mark J MJ; Caro, Pilar P; Oxley, David D; Ashton, Susan S; Adams, David J DJ; Saez-Rodriguez, Julio J; Smith, Paul D PD; Cook, Simon J SJ
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.
Oncogenesis
Wyce, Anastasia A; Matteo, Jeanne J JJ; Foley, Shawn W SW; Felitsky, Daniel J DJ; Rajapurkar, Satyajit R SR; Zhang, Xi-Ping XP; Musso, Melissa C MC; Korenchuk, Susan S; Karpinich, Natalie O NO; Keenan, Kathryn M KM; Stern, Melissa M; Mathew, Lijoy K LK; McHugh, Charles F CF; McCabe, Michael T MT; Tummino, Peter J PJ; Kruger, Ryan G RG; Carpenter, Christopher C; Barbash, Olena O
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
Therapeutic Advances In Medical Oncology
Milewska, Malgorzata M; Cremona, Mattia M; Morgan, Clare C; O'Shea, John J; Carr, Aoife A; Vellanki, Sri H SH; Hopkins, Ann M AM; Toomey, Sinead S; Madden, Stephen F SF; Hennessy, Bryan T BT; Eustace, Alex J AJ
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.
Molecular Cancer
Berg, Kaja C G KCG; Eide, Peter W PW; Eilertsen, Ina A IA; Johannessen, Bjarne B; Bruun, Jarle J; Danielsen, Stine A SA; Bjørnslett, Merete M; Meza-Zepeda, Leonardo A LA; Eknæs, Mette M; Lind, Guro E GE; Myklebost, Ola O; Skotheim, Rolf I RI; Sveen, Anita A; Lothe, Ragnhild A RA
CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network.
Oncotarget
Fertig, Elana J EJ; Ozawa, Hiroyuki H; Thakar, Manjusha M; Howard, Jason D JD; Kagohara, Luciane T LT; Krigsfeld, Gabriel G; Ranaweera, Ruchira S RS; Hughes, Robert M RM; Perez, Jimena J; Jones, Siân S; Favorov, Alexander V AV; Carey, Jacob J; Stein-O'Brien, Genevieve G; Gaykalova, Daria A DA; Ochs, Michael F MF; Chung, Christine H CH
Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.
Plos One
Dumble, Melissa M; Crouthamel, Ming-Chih MC; Zhang, Shu-Yun SY; Schaber, Michael M; Levy, Dana D; Robell, Kimberly K; Liu, Qi Q; Figueroa, David J DJ; Minthorn, Elisabeth A EA; Seefeld, Mark A MA; Rouse, Meagan B MB; Rabindran, Sridhar K SK; Heerding, Dirk A DA; Kumar, Rakesh R